<?xml version="1.0" encoding="UTF-8"?>
<p id="Par42">In the Netherlands, all patients with advanced and metastatic melanoma are treated in one of the 14 designated Dutch melanoma centres. The current nationwide study is executed in all 14 Dutch melanoma centres, which have close collaborations within the WIN-O (Dutch Working group on Immunotherapy of Oncology) and DMTR (Dutch Melanoma Treatment Registry): Amphia Hospital, Breda; Amsterdam University Medical Centres – location VU, Amsterdam; Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam; Erasmus Medical Centre Cancer Institute, Rotterdam; Isala Clinics, Zwolle; Leiden University Medical Centre, Leiden; Maastricht University Medical Centre+, Maastricht; Máxima Medical Centre, Veldhoven; Medical Centre Leeuwarden, Leeuwarden; Medical Spectrum Twente, Enschede; Radboud University Medical Centre, Nijmegen; University Medical Centre Groningen, Groningen; University Medical Centre Utrecht, Utrecht; Zuyderland Medical Centre, Sittard-Geleen. In December 2018, the first site (Erasmus Medical Centre Cancer Institute) opened for inclusion. At the moment, all sites are open for inclusion.</p>
